TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and shuttered businesses. Here are five biopharma players staying alive with differentiated candidates against the once promising immuno-oncology target.
Four Therapies Hanging On in Troubled TIGIT Space Read More »
El interés por métodos innovadores que favorezcan el bienestar cotidiano ha impulsado el desarrollo de soluciones tecnológicas no invasivas, diseñadas para integrarse fácilmente en la rutina. Una de las propuestas que ha captado la atención en el & …
Parches LifeWave: Bienestar diario con tecnología de fototerapia Read More »
Voyager Therapeutics unlocked a potential $600 million plus $25 million upfront as Novartis exercised its option to leverage the company’s capsids against two undisclosed neurologic disease targets.
Voyager Rolls on as Novartis Selects Two of Three CNS Targets Read More »
The transcatheter repair clip beat the established medical therapy on the primary composite endpoint, setting up a battle with a rival company for a $5 billion market.
Follow along as BioSpace keeps you up-to-date on which companies are tightening their belts and cutting staff throughout 2023.
BioSpace Layoff Tracker 2023: atai, MorphoSys, G1 and More Cut Staff Read More »
The FDA set a decision date of July 6, 2023 for Eisai and Biogen’s recently approved Alzheimer’s drug, Leqembi, Eisai announced Monday.
FDA Sets July Decision Date for Full Approval of Leqembi Read More »
With the results from the CLEAR outcomes study, Esperion is poised for a major inflection in sales and is targeting blockbuster status, said CEO Sheldon Koenig on an investor call Monday.
Full Results from Esperion’s Cholesterol Drug Fail to Impress Investors Read More »
Here are some tips to help you nail virtual interviews and networking events so you can be prepared for BioSpace’s Virtual Talent Connect on March 9.
How to Nail Virtual Interviews & Networking Events Read More »
Incyte Corporation’s Phase III LIMBER-304 clinical trial has come to an end following a third-party investigation that forecasted poor results.
Incyte Abandons Phase III Trial for Myelofibrosis Treatment Read More »
[et_pb_section bb_built=”1″][et_pb_row][/et_pb_row][/et_pb_section][et_pb_section bb_built=”1″ fullwidth=”off” specialty=”off”][et_pb_row][et_pb_column type=”1_4″][et_pb_team_member _builder_version=”3.0.99″ image_url=”https://convitgroup.com/wp-content/uploads/2018/02/Jacinto-Convit.jpg” name=”Jacinto Convit García” position=”Investigador” background_layout=”light”] “You have to love and let yourself go. Hatred kills, love heals ” September 11, 1913 – Mayo12, 2014 [/et_pb_team_member][/et_pb_column][et_pb_column type=”3_4″][et_pb_text _builder_version=”3.0.99″ background_layout=”light”] Jacinto Convit García was a Venezuelan physician and scientist, known for developing a vaccine to fight leprosy and his
